Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.53 |
| ▸ | PDE5A | O76074 | 6/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402896 | 0.90 | PDE4B (0.49) | PDE4BPDE5ANR3C1MEN1MAPT | |
| SCHEMBL987741 | 0.82 | PDE4B (0.60) | PDE4BPDE5ANR3C1MEN1MAPT | |
| SCHEMBL983832 | 0.78 | PDE4B (0.82) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL13987140 | 0.75 | PDE4B (0.72) | PDE4BPDE5AMEN1MAPTBLM | |
| SCHEMBL11602099 | 0.74 | PDE4B (0.65) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL11786785 | 0.73 | PDE4B (0.74) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL11603208 | 0.73 | PDE4B (0.64) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL5928041 | 0.72 | PDE4B (0.76) | PDE4BPDE5AMEN1MAPTHPGD | |
| Cartazolate SCHEMBL123839 | 0.69 | PDE4B (1.00) | PDE4BPDE5AMEN1MAPTHPGD | |
| SCHEMBL4341828 | 0.69 | NR3C1 (0.71) | PDE4BPDE5ANR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | BASILEA PHARMACEUTICA AG (CH) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021449-A1 | MACROLIDES AND USES OF MACROLIDES | MRPS22, MRPS23, MRPL12 | PDE4B 2412/4885PDE5A 3491/4885NR3C1 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.